Assessment of the biological and pharmacological effects of the αvβ3 and αv β5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1400-1407

  Hariharan, S ^a   Gustafson, D ^a   Holden, S ^a   McConkey, D ^b   Davis, D ^c   Morrow, M ^a   Basche, M ^a   Gore, L ^a   Zang, C ^a   O'Bryant, C L ^a   Baron, A ^a   Gallemann, D ^d   Colevas, D ^e   Eckhardt, S Gail ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ApoCell Inc   (United States)

^d MERCK KGAA   (Germany)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cilengitide; Integrins; Phase I trials

Indexed keywords

ALPHAVBETA5 INTEGRIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CILENGITIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE; VASCULOTROPIN; VITRONECTIN RECEPTOR ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENDOTHELIUM CELL; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MALE; MELANOMA; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; INTEGRIN ALPHAVBETA3; INTEGRINS; NEOPLASMS; RECEPTORS, VITRONECTIN; SNAKE VENOMS;

EID: 34548175694     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm140     Document Type: Article

References (42)

1. Ruegg C, Postigo A, Sikorski E et al. Role of integrin α4β7/α4βP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol 1992; 117: 179-189.
2. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-571.
3. Max R, Gerritsen RR, Nooigen PT et al. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 706-707.
4. Ronziere MC, Aubert-Foucher E, Goutenoire J et al. Integrin alpha1beta1 mediates oollagen induction of MMP-13 expression MC615 chondrocytes. Biochim Biophys Acta 2005; 1746: 55-64.
5. Barja-Fidalgo C, Coelho AL, Saldanha-Gama R et al. Disintegrins: integrin selective ligands which activate integrin-coupled signaling and modulate leukocyte functions. Braz J Med Biol Res 2005; 38: 1513-1520.
6. Chen H, Huang XN, Yan W et al. Role of the integrin-linked kinase/PINCH1/ alpha-parvin complex in cardiac myocyte hypertrophy. Lab Invest 2005; 85: 1342-1356.
7. Liu J, DeYoung SM, Zhang M et al. Changes in integrin expression during adipocyte differentiation. Cell Metab 2005; 2: 165-177.
8. Asano Y, Ihn H, Yamane K et al. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-1292.
9. Meredith JE, Fazell B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-961.
10. Hynes R. Integrins: Bidirectional, allosteric signaling machines. Cell 2000; 110: 673-687.
11. Ginsberg MH, Partridge A, Shattill SJ et al. Integrin regulation. Curr Opin Cell Biol 2005; 17: 509-516.
12. Duan X, A Jia SF, Zhou Z et al. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis 2004; 21: 747-753.
13. Abdollahi A, Griggs DW, Zieher H et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-6279.
14. Lyons AJ, Jones X-T Xie J. Integrins in metastatic adenold cystic carcinoma. Int J Oral Maxillofac Surg 2005, 34: 912-914.
15. Vellon L, Menendez JA, Lupu R. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 2005; 24(23): 3759-3773.
16. Kageshita T, Hamby CY, Hirai S et al. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: Differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 2000; 49(6): 314-318.
17. Sun YX, Fang M, Wang J et al. Expression and activation of alpha(v)beta(3) Integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007: 67(1): 61-73.
18. Goodman SL, Holzemann G, Sulyok GA et al. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem 2002; 45: 1045-1051.
19. Dechantsreiter MA, Planka E, Matha B et al. Methylated cyclic RGD peptides as highly active and selective alphavbeta(3) integrin antagonists. J Med Chem 1999; 42: 3033-3040.
20. Nisato RE, Tille JC, Jonczyk A et al. Alphavbeta3 and alphavbeta5 integrin antagonists inhibit anglogenesis in vitro. Angiogenesis 2003; 6: 105-119.
21. Mitjans F, Meyer T, Fittschen C et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000; 87(5): 716-723.
22. MacDonald TJ, Taga T, Shimada H et al. Preferential susceptibility of brain tumors to the antianglogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151-157.
23. Eskens FALM, Dumez H, Hoekstra R et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumors. Eur J Can 2003; 39: 917-926.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Meyrin W. EMD121974: Validation of an HPLC-MS/MS Method for the Quantification of EMD121974 in Human Plasma. Study Report. Darmstadt, Germany. Merck KGaA 2003.
26. Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998; 4: 3017-3024.
27. Shaheen RM, Davis DW, Liu W et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412--5416.
28. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94 (12): 883-893.
29. Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12 (10): 3124-3129.
30. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23 (15): 3502-3508.
31. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (16): 2505-2512.
32. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients wfth metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (1): 16-24.
33. Hehlgans S, Haase M, Cordes N. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007; 1775 (1): 163-180.
34. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18 (5): 516-523.
35. Posey A, Khazaeli MB, DelGrosso A et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001; 16 (2): 125-132.
36. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5): 427-434.
37. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients wfth advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368 (9544): 1329-1338.
38. Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006; 10 (4 Suppl 21): 1-12.
39. Sandler A, Gray R, Perry MC et al. Paciitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-2550.
40. Friess H, Langrehr JM, Oettle H et al. A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006; 6 (1): 285.
41. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87 (2): 161-167.
42. Phase III Study of Avastin(R) in Advanced Pancreatic Cancer does not meet Primary Endpoint. Life Sciences World 2006; www.lifesciencesworld.com/news/view/7575.